PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: PF-07264660
Other: Placebo

First Posted Date: 2024-12-02

Last Posted Date: 2025-04-20

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT06712082

Locations: 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-07258669
Drug: Itraconazole

First Posted Date: 2024-11-27

Last Posted Date: 2025-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT06706869

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸
Research Centers of America, Hollywood, Florida, United States

A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tafamidis 61 mg free acid tablet (Test)
Drug: Tafamidis 61 mg free acid capsule (Reference)

First Posted Date: 2024-11-26

Last Posted Date: 2025-05-28

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT06705569

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1

Recruiting

Conditions: Carcinoma, Pancreatic Ductal
Colorectal Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: PF-07985045
Combination Product: Gemcitabine
Combination Product: Cetuximab
Combination Product: Fluorouracil
Combination Product: Pembrolizumab
Combination Product: PF-07284892
Combination Product: Nab-paclitaxel
Combination Product: Oxaliplatin
Combination Product: Sasanlimab
Combination Product: pemetrexed
Combination Product: Leucovorin
Combination Product: Cisplatin
Combination Product: Bevacizumab
Combination Product: Paclitaxel
Combination Product: Carboplatin

First Posted Date: 2024-11-26

Last Posted Date: 2025-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 190

Registration Number: NCT06704724

Locations: 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
City of Hope (City of Hope National Medical Center, City Of Hope Medical Center), Duarte, California, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 5 locations

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Phase 1

Recruiting

Conditions: Severe Hemophilia A

Interventions: Drug: MARSTACIMAB

First Posted Date: 2024-11-25

Last Posted Date: 2025-05-29

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT06703606

Locations: 🇺🇸
Orthopaedic Institute for Children, Los Angeles, California, United States

Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine

Active, not recruiting

Conditions: COVID-19

Interventions: Biological: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated
Biological: Not vaccinated with 2024-2025 formulated COVID-19 vaccine

First Posted Date: 2024-11-25

Last Posted Date: 2025-05-29

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06703190

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

Phase 3

Recruiting

Conditions: Dermatomyositis
Polymyositis

Interventions: Drug: Dazukibart

First Posted Date: 2024-11-21

Last Posted Date: 2025-04-15

Lead Sponsor: Pfizer

Target Recruit Count: 211

Registration Number: NCT06698796

Locations: 🇧🇬
Medical Center Artmed, Plovdiv, Bulgaria
🇺🇸
Rheumatology & Pulmonary Clinic, Beckley, West Virginia, United States
🇨🇳
Beijing Peking Union Medical College Hospital, Beijing, Beijing, China

A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults

Phase 1

Completed

Conditions: SARS-CoV-2 Infections

Interventions: Drug: Treatment B
Drug: Treatment A

First Posted Date: 2024-11-18

Last Posted Date: 2025-01-24

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT06693518

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: PF-08049820
Drug: Placebo

First Posted Date: 2024-11-13

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT06686797

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Completed

Conditions: Migraine

First Posted Date: 2024-11-08

Last Posted Date: 2024-12-31

Lead Sponsor: Pfizer

Target Recruit Count: 1363

Registration Number: NCT06680206

Locations: 🇺🇸
Pfizer, New York, New York, United States

Home Terms & Conditions Privacy Policy